Pacer Advisors’s ResMed RMD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $114M | Buy |
506,378
+26,466
| +6% | +$6.6M | 0.32% | 74 |
|
|
2025
Q4 | $116M | Buy |
479,912
+349,713
| +269% | +$89.4M | 0.3% | 75 |
|
|
2025
Q3 | $35.6M | Buy |
130,199
+27,453
| +27% | +$7.5M | 0.09% | 221 |
|
|
2025
Q2 | $26.5M | Buy |
102,746
+64,743
| +170% | +$15.4M | 0.07% | 258 |
|
|
2025
Q1 | $8.51M | Sell |
38,003
-6,689
| -15% | -$1.56M | 0.02% | 508 |
|
|
2024
Q4 | $10.2M | Buy |
44,692
+15,345
| +52% | +$3.69M | 0.02% | 455 |
|
|
2024
Q3 | $7.16M | Buy |
29,347
+5,483
| +23% | +$1.23M | 0.02% | 543 |
|
|
2024
Q2 | $4.57M | Buy |
23,864
+13,903
| +140% | +$2.82M | 0.01% | 608 |
|
|
2024
Q1 | $1.97M | Buy |
9,961
+267
| +3% | +$48.9K | ﹤0.01% | 873 |
|
|
2023
Q4 | $1.67M | Sell |
9,694
-4,458
| -32% | -$685K | ﹤0.01% | 848 |
|
|
2023
Q3 | $2.09M | Buy |
14,152
+870
| +7% | +$157K | 0.01% | 593 |
|
|
2023
Q2 | $2.9M | Buy |
13,282
+2,429
| +22% | +$541K | 0.01% | 635 |
|
|
2023
Q1 | $2.38M | Buy |
10,853
+10,329
| +1,971% | +$2.24M | 0.01% | 680 |
|
|
2022
Q4 | $109K | Sell |
524
-2,314
| -82% | -$508K | ﹤0.01% | 2577 |
|
|
2022
Q3 | $620K | Sell |
2,838
-206
| -7% | -$46.9K | ﹤0.01% | 675 |
|
|
2022
Q2 | $638K | Sell |
3,044
-4,437
| -59% | -$945K | ﹤0.01% | 635 |
|
|
2022
Q1 | $1.81M | Sell |
7,481
-2,104
| -22% | -$509K | 0.01% | 644 |
|
|
2021
Q4 | $2.5M | Sell |
9,585
-527
| -5% | -$137K | 0.03% | 713 |
|
|
2021
Q3 | $2.67M | Sell |
10,112
-476
| -4% | -$130K | 0.03% | 606 |
|
|
2021
Q2 | $2.61M | Buy |
10,588
+2,608
| +33% | +$548K | 0.04% | 535 |
|
|
2021
Q1 | $1.55M | Sell |
7,980
-827
| -9% | -$166K | 0.03% | 597 |
|
|
2020
Q4 | $1.87M | Sell |
8,807
-4,145
| -32% | -$826K | 0.04% | 457 |
|
|
2020
Q3 | $2.22M | Sell |
12,952
-2,198
| -15% | -$406K | 0.05% | 381 |
|
|
2020
Q2 | $2.91M | Buy |
+15,150
| New | +$2.48M | 0.06% | 239 |
|
|
2020
Q1 | – | Sell |
-15,879
| Closed | -$2.46M | – | 1022 |
|
|
2019
Q4 | $2.46M | Sell |
15,879
-1,087
| -6% | -$157K | 0.11% | 208 |
|
|
2019
Q3 | $2.29M | Buy |
16,966
+1,516
| +10% | +$199K | 0.05% | 430 |
|
|
2019
Q2 | $1.89M | Buy |
15,450
+2,703
| +21% | +$299K | 0.05% | 511 |
|
|
2019
Q1 | $1.33M | Buy |
+12,747
| New | +$1.32M | 0.04% | 387 |
|
|
2018
Q4 | – | Sell |
-7,687
| Closed | -$887K | – | 940 |
|
|
2018
Q3 | $887K | Buy |
7,687
+1,102
| +17% | +$121K | 0.03% | 691 |
|
|
2018
Q2 | $682K | Buy |
6,585
+1,116
| +20% | +$113K | 0.03% | 801 |
|
|
2018
Q1 | $539K | Buy |
5,469
+616
| +13% | +$58.2K | 0.03% | 719 |
|
|
2017
Q4 | $411K | Buy |
4,853
+1,632
| +51% | +$135K | 0.03% | 769 |
|
|
2017
Q3 | $248K | Buy |
3,221
+297
| +10% | +$22.7K | 0.02% | 938 |
|
|
2017
Q2 | $228K | Buy |
2,924
+225
| +8% | +$16.1K | 0.02% | 949 |
|
|
2017
Q1 | $194K | Buy |
2,699
+79
| +3% | +$5.46K | 0.02% | 938 |
|
|
2016
Q4 | $163K | Sell |
2,620
-16
| -0.6% | -$980 | 0.02% | 927 |
|
|
2016
Q3 | $171K | Sell |
2,636
-20
| -0.8% | -$1.33K | 0.03% | 878 |
|
|
2016
Q2 | $168K | Buy |
2,656
+422
| +19% | +$24.9K | 0.03% | 874 |
|
|
2016
Q1 | $129K | Buy |
2,234
+190
| +9% | +$10.8K | 0.03% | 527 |
|
|
2015
Q4 | $110K | Buy |
+2,044
| New | +$115K | 0.03% | 557 |
|
Other funds holding RMD
VCM
VPM
DAM
Pacer Advisors's RMD Position: Q1 2026 in Review
Pacer Advisors increased its ResMed (RMD) stake by 5.5% in Q1 2026, buying an estimated $6.6M and bringing the position to 506,378 shares worth $114M. The position accounts for 0.32% of the portfolio, ranked #74.
Pacer Advisors first reported a position in RMD in Q4 2015 and has held it in 40 quarters since. The position peaked at $116M in Q4 2025. 938 funds tracked by Wall St. Rank hold RMD as of Q1 2026.
- Pacer Advisors held 506,378 shares of ResMed worth $114M as of Q1 2026.
- Pacer Advisors bought 26,466 ResMed shares in Q1 2026, an estimated $6.6M.
- ResMed made up 0.32% of Pacer Advisors's portfolio in Q1 2026, its #74 holding.
- Pacer Advisors first reported a position in ResMed in Q4 2015 and has held it in 40 quarters since.
- Pacer Advisors's ResMed position peaked at $116M in Q4 2025.
- 938 funds tracked by Wall St. Rank held ResMed as of Q1 2026.
Based on Pacer Advisors's 13F filing for Q1 2026, filed 6 May 2026.